Clinical trial · Observational
Oligosecretary Myeloma: Prevalence and Its Clinical Significance
NCT02095379CI-TRIAL-00014089completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators aim to investigate the prevalence and clinical course of oligosecretary myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| oligosecretary | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- oligosecretary
- description
- Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
- interventionNames
- Other: oligosecretary
Primary outcomes (1)
- measure
- Number of patients with oligosecretary myeloma among multiple myeloma patients
- timeFrame
- up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day) * available clinical data Exclusion Criteria: * patients without available clinical data
References
Publications (0)
Data not yet available
No reference posted for this study.